THE WIRE · № 75079
Moderna, $MRNA, is now up more than 600% this year. It started 2026 at about $29, now at $225. It’s one of the best-performing stock in the S&P 500. The run: August: jumped 140% in a single day on positive late-stage melanoma vaccine data September: kept climbing toward $200
01 THE MACHINE READ
WHY IT MATTERS.
Moderna's surge on cancer-vaccine data highlights biotech catalyst-driven upside and sector momentum.
Moderna's cancer-vaccine run lifts biotech sentiment
Further trial data and NIH policy news
Clinical or policy setbacks could reverse gains
FULL DISPATCH
Moderna, $MRNA, is now up more than 600% this year. It started 2026 at about $29, now at $225. It’s one of the best-performing stock in the S&P 500. The run: August: jumped 140% in a single day on positive late-stage melanoma vaccine data September: kept climbing toward $200 On Oct 9: up 14% after reports the NIH will push to speed up personalized cancer vaccines
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
The gap between AI names and the rest of the market is historic: Since the start of 2024, a basket of 42 AI stocks has generated 67% of the S&P 500's price return. In other words, those names have contributed +22 percentage points to the index’s +33% gain over this period. By2026-10-11 19:31 UTC
The S&P 500 is up about 14% this year. Its top stocks are up several hundred percent: Sandisk: +578% Moderna: +568% Dell: +361% Micron: +263% Marvell: +224%2026-10-11 21:01 UTC
BREAKING: 84% of S&P 500 stocks are now trading at least -10% below their all-time highs. Real Estate leads the drawdown, with 97% of stocks down at least -10%, followed by Materials at 96%, Utilities at 94%, and Consumer Discretionary at 92%. By comparison, Energy has held up2026-10-11 21:32 UTC
Dow, S&P 500, Nasdaq Futures Climb After Oil In Focus As Trump Declares ‘Energy Ceasefire’ Between Russia And Ukraine: IREN, WFF, VSTM, CIFR Stocks In Focus2026-10-12 03:50 UTC
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer2026-10-10 04:41 UTC
Economic Pain and an Unpopular Trump Put G.O.P. on its Heels With Three Weeks to Go2026-10-10 09:01 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.